ANI Pharmaceuticals
ANIP
151 hedge funds and large institutions have $305M invested in ANI Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 62 increasing their positions, 48 reducing their positions, and 23 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 48
4% more capital inflows, than outflows
Capital inflows: $46.3M | Capital outflows: $44.7M
0.14% more ownership
Funds ownership: 55.68% → 55.82% (+0.14%)
4% less funds holding
Funds holding: 158 → 151 (-7)
26% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 23
89% less call options, than puts
Call options by funds: $1.11M | Put options by funds: $9.86M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$10.7M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$7.8M |
| 3 |
First Manhattan
New York
|
+$4.74M |
| 4 |
Morgan Stanley
New York
|
+$2.89M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$2.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
-$7.56M |
| 2 |
PA
Perceptive Advisors
New York
|
-$6.25M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$5.63M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$5.28M |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$2.89M |
ANIP Hedge Fund Activity: Q2 2017 in Review
151 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q2 2017, worth a combined $305M — down 4.5% from $320M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of ANIP and 17 opened new positions — a net loss of 6 holders — while 48 trimmed existing stakes and 62 added.
The largest buyer was Mangrove Partners, adding an estimated $10.7M. The largest seller was Fiera Capital (Canada), exiting entirely with an estimated $7.56M sold.
- 151 institutional investors held ANI Pharmaceuticals (ANIP) as of Q2 2017, down from 158 in Q1 2017.
- Funds reported $305M of ANI Pharmaceuticals stock for Q2 2017, down 4.5% quarter-over-quarter.
- 17 funds opened new ANI Pharmaceuticals positions in Q2 2017 and 23 closed out, a net change of -6 holders.
- The largest ANI Pharmaceuticals buyer in Q2 2017 was Mangrove Partners, an estimated $10.7M added.
- The largest ANI Pharmaceuticals seller in Q2 2017 was Fiera Capital (Canada), an estimated $7.56M sold.
Based on aggregated 13F filings for Q2 2017.